BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO) Amid Solid SubQ Amycretin Results
Go back to BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO) Amid Solid SubQ Amycretin Results| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 45.89 -0.83 (1.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.72 | 52 Week High | $59.00 | |||
| Open | $46.90 | 52 Week Low | $32.80 | |||
| Day High | $47.05 | P/E | N/A | |||
| Day Low | $45.75 | EPS | $0.00 | |||
| Volume | 10,851,603 | |||||
